| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() ASBD: Recurring Phyllodes Tumors Have Poor Prognosis, Study Shows By Linda Little LAS VEGAS, NV -- April 20, 2005 -- Phyllodes tumor of the breast, an uncommon type of breast cancer that rarely recurs, is associated with short survival, according to a study presented during a poster session at the American Society of Breast Disease annual meeting. Phyllodes tumors occur in about 1% to 3% of all breast cancers. They are bi-tissue, fibro-epithelial tumors, with a predominant connective tissue component. Surgical resection is the mainstay of treatment, but the extent of surgery and indications for additional therapy are unclear. Mastectomy is often recommended in cases of large or aggressively active tumors. Flavia Morales-Vásquez, MD, led researchers from the Instituto Nacional de Cancerología de México, in México City, Mexico, and the University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States, in a study of 199 patients with phyllodes tumor of the breast. In the retrospective study, the researchers studied the women, who were an average age of 40 years of age, during a 7-year period. They tabulated patient characteristics and recurrence-free survival. All patients underwent surgery with 34% receiving breast conservation surgery and 66% undergoing mastectomy; 18% had axillary nodal dissection. Only patients with high grade tumors received adjuvant chemotherapy and/or radiotherapy. Median tumor size was 6 cm, with 87% classified as low-grade. The median disease-free survival exceeded 180 months, with recurrence-free survival significantly longer in patients with low grade tumors, those without papable nodes, and those who did not no have axillary dissection or receive adjuvant chemotherapy or radiotherapy. The extent of surgery and positive margins had no impact on recurrence-free survival, the researchers said. Although the risk of recurrence of this form of breast cancer is low, the prognosis is not good when it does recur. The women in this study had a median survival after recurrence of 6.5 months. More aggressive interventions in patients at high risk for recurrence should be studied, the researchers recommended.
[Presentation title: Phyllodes Tumor of the Breast, Features at Presentation and Survival. Poster 13]
|